Introduction
Systemic administration of corticotrophin releasing factor (CRF) or the structurally homologous peptides urocortin, urotensin I, and sauvagine (SVG), cause profound long-lasting reductions in blood pressure (BP) in anaesthetised and conscious animals. [1] [2] [3] These responses are associated with sustained vasodilatation in a number of tissues.
1,2 Recent investigations of the underlying mechanisms of these responses using isolated preparations have shown the vasodilator effect of CRF to involve both a direct action on vascular smooth muscle and a prolonged endothelium-dependent response due to the sustained release of nitric oxide (NO). 4 In the experiments described here, the role of endothelium derived NO release in the sustained hypotensive effect of CRF has been evaluated using the NO synthase inhibitor N G -Nitro-L-arginine Methyl Ester (L-NAME) in anaesthetised rats. The effect of L-NAME on CRF-induced reductions in mean arterial blood pressure (MAP) was investigated either as a pre-treatment administered by infusion or by bolus injection after CRF.
Materials and methods
Male Wistar rats (Ϸ250 g) were anaesthetised with sodium thiopentone (120 mg/kg −1 i.p.). MAP was continually recorded from the right carotid artery. Cannulae inserted in the left jugular vein and left femoral artery were used for bolus injections and Correspondence: Dr R Corder injection. Bolus injection of L-NAME produced a marked vasopressor effect when given alone. However, when administered 20 min after CRF, L-NAME restored MAP to basal levels, but the marked vasopressor response observed in control animals was completely blocked. This indicates that the increase in BP occurring on bolus injection of L-NAME is not simply due to an inhibition of NO-dependent vasodilatation.
infusion of agents respectively. The effects of L-NAME (Calbiochem, San Diego, CA, USA) on the response to CRF (4 nmol/kg) were evaluated by constant infusion of L-NAME (1 or 10 mg/kg/min) followed by a bolus dose of CRF, or by administering L-NAME as a bolus injection (10 mg/kg) 20 min after CRF administration. In addition, for comparison with L-NAME infusion, MAP was increased to a similar level by an infusion of noradrenaline (30 g/kg/min). Because of the marked effect of L-NAME infusion on MAP, the CRF responses during the infusion studies are reported as % changes to show relative differences.
Results
In anaesthetised rats CRF caused a sustained reduction in MAP. Infusion of L-NAME increased baseline MAP but the effect of CRF was not blocked (Figure 1) . Similarly, the response during noradrenaline infusion was of similar magnitude to that in control rats or during L-NAME infusion. When L-NAME was administered as a bolus 20 min after CRF, MAP returned to pre-CRF levels less than 5 min after L-NAME and did not increase further (Figure 2 ). This contrasted markedly with the response in control rats given L-NAME alone, where MAP increased by 67 ± 6 mm Hg and remained elevated for more than 20 min. The increase in MAP when L-NAME was given alone was significantly greater (P Ͻ 0.001) at all time points than the response in CRF pre-treated animals. 
Conclusions
Compared to other vasodilator agents acting via the release of NO, CRF or sauvagine cause sustained vasodilator responses through prolonged release of NO suggesting a novel mechanism of activation of nitric oxide synthase. 4 The results described here indicate that the strikingly long-lasting hypotensive effect of CRF in vivo is probably not due simply to NO release. Despite the frequently observed vasopressor effect of NOS inhibitors administered systemically it is has often proved difficult to block endothelium-dependent vasodilator responses in vivo. 5 Hence, the fact that infusion of L-NAME did not prevent CRF-induced reductions in MAP was not unexpected.
Conversely, when L-NAME was administered after CRF, it appeared to restore BP to basal levels consistent with it inhibiting the endotheliumdependent effect of CRF. However, of greater interest was the inhibition of the vasopressor effect of L-NAME. This suggests the mechanism underlying the increase in MAP with L-NAME may not be due simply to inhibition of endothelium-dependent NO mediated vasodilatation. Earlier studies have indicated that activation of the sympathetic nervous system plays a significant part in the increase in MAP observed after NOS inhibition. 6, 7 Hence, it seems likely that CRF exerts an inhibitory effect on the sympathetic nervous system resulting in the complete blockade of this component of the L-NAME response. In agreement with this, CRF binding has been reported on sympathetic ganglia. 8 These results indicate that in vivo the sustained hypotensive effect of CRF involves not only a short-lasting vasodilatation of vascular smooth muscle and a prolonged endothelium-dependent response, but also a sympatho-inhibitory action.
